SAR Studies of N-[2-(1H-Tetrazol-5-yl)phenyl]benzamide Derivatives as Potent G Protein-Coupled Receptor-35 Agonists

G protein-coupled receptor-35 (GPR35) has emerged as a potential target in the treatment of pain and inflammatory and metabolic diseases. We have discovered a series of potent GPR35 agonists based on a coumarin scaffold and found that the introduction of a 1 H- tetrazol-5-yl group significantly increased their potency. We designed and synthesized a new series of N- [2-(1 H- tetrazol-5-yl)phenyl]benzamide derivatives through a two-step synthetic approach, and characterized their agonistic activities against GPR35 using a dynamic mass redistribution (DMR) assay. N- (5-bromo-2-(1 H- tetrazol-5-yl)phenyl)-4-methoxybenzamide ( 56 ) and N- (5-bromo-2-(1 H- tetrazol-5-yl)phenyl)-2-fluoro-4-methoxybenzamide ( 63 ) displayed the highest agonistic potency agonist GPR35 with an EC 50 of 0.059 μM and 0.041 μM, respectively. The physicochemical properties of selected compounds were calculated to evaluate their druglikeness, suggesting that compounds 56 and 63 have good druglike properties. Together, N -[2-(1H-tetrazol-5-yl)phenyl]benzamide derivatives are potentially great candidates for developing potent GPR35 agonists.